Table 1.
List of major miRNAs identified as biomarkers in B-cell malignancies.
| Lymphoma | Biomarker | miRNA | Sample | References |
|---|---|---|---|---|
| HL | Diagnostic | miR-155 | Cell lines | van den berg et al25 and Metzler et al26 |
| 23-miRNA signature | Cell lines | Gibcus et al27 | ||
| 25-miRNA signature | Tissue | Navarro et al28 | ||
| 134- and 100-miRNA signature | Cell lines and tissue | Sanchez-Espiridion et al29 | ||
| miR-9-2 (methylation) | Tissue | Ben Dhiab et al30 | ||
| Prognostic | miR-135a | Tissue and cell lines | Navarro et al31 | |
| miR-21, miR-30e/d, and miR-92b | Tissue | Sanchez-Espiridion et al29 | ||
| miR-124a (methylation) | Tissue | Ben Dhiab et al32 | ||
| CLL | Diagnostic | miR-15a/16 cluster | PBMCs and cell lines | Calin et al33 |
| miR-7, miR-182, and miR-320c/d | PBMCs and cell lines | Blume et al34 | ||
| miR-29 | PBMCs and cell lines | Pekarsky et al35 | ||
| miR-151 | Serum (EV) | Caivano et al36 | ||
| miR-34a, miR-31, miR-155, miR-150, miR-15a, miR-29a | Serum | Filip et al37 | ||
| miR-192 | PBMCs | Fathullahzadeh et al38 | ||
| Prognostic | miR-181b | PBMCs | Visone et al39 | |
| miR-21 | PBMCs | Rossi et al40 | ||
| miR-155 | PBMCs | Cui et al41 | ||
| miR-708 | PBMCs and cell lines | Baer et al42 | ||
| miR-150 | Cell lines and serum | Stamatopoulos et al43 | ||
| miR-150 and miR-155 | Blood cells | Georgiadis et al44 | ||
| miR-17~92 cluster | PBMCs | Bomben et al45 | ||
| 13-miRNA signature | PBMCs and cell lines | Calin et al46 | ||
| Predictive | miR-181b | PBMCs | Rossi et al40 | |
| miR-155 | PBMCs | Ferrajoli et al47 | ||
| miR-21*, miR-148a, and miR-222 | PBMCs and cell lines | Ferracin et al48 | ||
| DLBCL | Diagnostic | miR-21, miR-155, and miR-210 | Serum | Lawrie et al24 |
| 12-miRNA signature | Tissue | Roehle et al49 | ||
| 15-miRNA signature | Tissue | Lawrie et al50 | ||
| 12-miRNA signature | Tissue | Caramuta et al51 | ||
| miR-155, miR-221, miR-222, miR-21, miR-363, miR-518a, miR-181a, miR-590, miR-421, and miR-324 | Cell lines | Lawrie et al52 | ||
| miR-155 and miR-146a | Tissue | Zhong et al53 | ||
| 27-miRNA signature | Tissue and cell lines | Iqbal et al54 | ||
| miR-124, miR-532, miR-122, miR-128, miR-141, miR-145, miR-197, miR-345, miR-424, and miR-425 | Plasma and exosomes | Khare et al55 | ||
| miR-34a, miR-323b, and miR-431 | Serum | Meng et al56 | ||
| Prognostic | miR-21 | Serum | Lawrie et al24 | |
| miR-155 and miR-146a | Tissue | Zhong et al53 | ||
| miR-22 | Serum | Marchesi et al57 | ||
| miR-155 | Tissue and cell lines | Iqbal et al54 | ||
| miR-20a and miR-30d | Tissue | Pillar et al58 | ||
| miR-155 | Tissue and cell lines | Zhang et al59 | ||
| miR-17~92 cluster | Tissue and cell lines | Tagawa et al60 | ||
| miR-34a | Tissue | He et al61 | ||
| miR-27b | Tissue | Jia et al62 | ||
| miR-21 | Cell lines | Gu et al63 | ||
| miR-21 | Tissue | Lawrie et al24 and Zheng et al64 | ||
| Predictive | miR-27a, miR-142, miR-199b, miR-222, miR-302, miR-330, miR-425, and miR-519 | Tissue | Lawrie et al50 | |
| miR-155 and miR-146a | Tissue | Zhong et al53 | ||
| miR-21 | Cell lines | Gu et al63 and Bai et al65 | ||
| miR-224, miR-455, miR-1236, miR-33a, and miR-520d | Serum | Song et al66 | ||
| miR-125b and miR-130a | Tissue and blood | Yuan et al67 | ||
| miR-199a and miR-497 | Tissue and cell lines | Troppan et al68 | ||
| miR-370, miR-381, and miR-409 | Tissue and cell lines | Leivonen et al69 | ||
| FL | Diagnostic | miR-9 and miR-155 | Tissue | Roehle et al49 |
| miR-217, miR-221, miR-222, miR-223, let-7i, and let-7b | Tissue | Lawrie et al50 | ||
| miR-31 and miR-17 | Tissue | Thompson et al70 | ||
| 17-miRNA signature | Tissue | Leich et al71 | ||
| 44-miRNA signature | Tissue | Wang et al72 | ||
| miR-494 | Tissue | Arribas et al73 | ||
| 66-miRNA signature | Bone marrow smears | Takei et al74 | ||
| Predictive | 23-miRNA signature | Tissue | Wang et al72 | |
| BL | Diagnostic | miR-23a, miR-26a, miR-29b, miR-30d, miR-146a, miR-146b, miR-155, and miR-221 | Tissue | Lenze et al75 |
| miR-34b | Cell lines and tissue | Leucci et al76 | ||
| 22-miRNA signature | Tissue | Hezaveh et al77 | ||
| miR-155, miR-21, and miR-26a | Needle aspirates | Zajdel et al78 | ||
| miR-29 family | Cell lines and tissue | Robaina et al79 and De Falco et al80 | ||
| miR-513a | Tissue | De Falco et al80 | ||
| miR-628 | Tissue | De Falco et al80 | ||
| miR-9* | Tissue | Onnis et al81 | ||
| 39-miRNA signature | Tissue | Robertus et al82 | ||
| 19-miRNA signature | Tissue | Di Lisio et al83 | ||
| 49-miRNA signature | Tissue | Oduor et al84 | ||
| miR-181b | Cell lines and tissue | Li et al85 | ||
| MCL | Diagnostic | miR-15/16 and miR-17~92 | Cell lines | Chen et al86 and Deshpande et al87 |
| 95-miRNA signature | Tissue | Iqbal et al88 | ||
| Prognostic | miR-15b | Tissue | Arakawa et al89 | |
| miR-129, miR-135, miR-146a, miR-424, miR-450, and miR-222 | Tissue | Iqbal et al88 | ||
| miR-17, miR-18a, miR-19b, and miR-92a (miR-17~92 cluster) | Tissue | Roisman et al90 | ||
| miR-29 | Cell lines and tissue | Zhao et al91 | ||
| miR-20b | Cell lines and tissue | Di Lisio et al92 | ||
| miR-18b | Cell lines and tissue | Husby et al93 | ||
| miR-223 | PBMCs and cell lines | Zhou et al94 | ||
| SMZL | Diagnostic | miR-29a, miR-29b-1, miR-96, miR-129, miR-182, miR-183, miR-335, and miR-593 | Tissue | Watkins et al95 |
| miR-127, miR-139, miR-335, miR-411, miR-451, and miR-486 | Tissue | Bouteloup et al96 | ||
| MALT | Diagnostic | 27-miRNA signature | Tissue | Thorns et al97 |
| miR-142, miR-155, and miR-203 | Tissue | Fernandez et al98 | ||
| Prognostic | miR-142 and miR-155 | Tissue | Liu et al99 |
Abbreviations: BL, Burkitt lymphoma; CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HL, Hodgkin lymphoma; miRNA, microRNA; MALT, mucosa-associated lymphoid tissue; MCL, mantle cell lymphoma; PBMCs, peripheral blood mononuclear cells; SMZL, splenic marginal zone lymphoma.
*the minor strand of the mature form of the miRNA